DBV Technologies | DBVT - Ebit

股票价格
19.65
每天变化
-0.19 -0.96%
每月一次
-4.66%
每年
77.03%
Q2 预测
19.19


金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 760.3M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


Ebit 更改 日
Acadia Pharmaceuticals USD -4.62M 22.01M 2026-03
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
Amarin USD -2.26M 564K 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
BioMarin Pharmaceutical USD 129.65M 68.74M 2026-03
DBV Technologies USD -34.28M 6.83M 2025-09
Esperion Therapeutics USD 85.23M 95.19M 2025-12
Galectin Therapeutics USD -9.17M 163K 2023-09
Halozyme Therapeutics USD -61.77M 26.64M 2026-03
Incyte USD 344.17M 39.71M 2026-03
Insmed USD -200.28M 49.43M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
PTC Therapeutics USD 45.89M 127.51M 2026-03
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
United Therapeutics USD 325.8M 340.4M 2026-03